"I'd be very surprised if we were to see any new drugs for depression in the next decade. The pharmaceutical industry is simply not investing in the research because it can't make money from these drugs http://finance.yahoo.com/news/no-antidepressants-sight-despite-growing-093604583.html
SABRIL'S patent expiration this year will have a MAJOR impact on Lundbeck! Read the link below regarding 2017 patent loses. Here we are losing a major part of the portfolio, and what do we do, fly the entire company to Dallas to hand out awards and role play!! There is NO fiscal responsibility at Lundbeck! You really can't make this stuff up! http://blog.dicksondata.com/wp-content/uploads/2017/01/2017_Patent_Infographic-01-e1483636228105.png
Read this: http://blog.dicksondata.com/wp-content/uploads/2017/01/2017_Patent_Infographic-01-e1483636228105.png
I wouldn't classify the posts as being in the "shy is falling" category. Which post(s) on this thread do you think are false or incorrect, and why? Just curious. To me, with Xenazine losing ground monthly, and Sabril going in a few months, that is grounds for being somewhat concerned. Just sayin'
"Somewhat concerned" is a massive understatement unless you are just looking at the next 12 months. With LOE of the orphan neuro products and NO pipeline, in short order this company will have nothing of value to sell. Show me the projected revenue at the start of 2019 that supports a company of 4000+ people. Crickets from management...
